<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03149523</url>
  </required_header>
  <id_info>
    <org_study_id>CARPEM_ExhauCRF</org_study_id>
    <nct_id>NCT03149523</nct_id>
  </id_info>
  <brief_title>Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors</brief_title>
  <acronym>ExhauCRF</acronym>
  <official_title>Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors to Define Potential Targets of Targeted and/or Immunomodulatory Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Georges Pompidou Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assistance Publique - HÃ´pitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Georges Pompidou Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over the last 10 years, technological advances in molecular biology enabled a more accurate
      genomic characterization of tumors. For each tumor location, this led to the identification
      of subgroups with similar molecular characteristics. This identification allowed the
      development of targeted therapies and thus to improve the patient prognosis. This molecular
      characterization has also revealed the tumor heterogeneity. It may be the cause of treatment
      resistance and therefore of relapses. Additionally, tumor cells are in constant dialogue with
      their microenvironment composed of different immune or non immune cells. This
      microenvironment is now targeted in cancer treatment.

      To date, there are few studies that combine a deep genomic characterization of both tumor and
      tumor microenvironment of the patient. Combining the two types of studies on the same tumor
      should help to define new therapeutic targets and should allow a combination of targeted and
      immunomodulatory therapies. To this end, our project is to conduct an exhaustive integrated
      exploratory analysis at genomic, transcriptomic and immunological levels of 3 tumor types (in
      colon, kidney and liver cancer).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The design consists in recruiting 50 patients per tumor location (colon, kidney, liver). For
      colorectal and kidney cancers, a prospective enrollment will be done for patients who have
      consented to the study. A retrospective enrollment will be done for patients with liver
      cancer only and who have consented to a national biological resource center form with genetic
      study approval.

      The tumor samples will be taken during surgery. Blood and tumors samples will be taken as
      part of the treatment.

      In case of a accidental germline discovery a management by a genetic consulting will be
      proposed.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2017</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sequencing of the exome and tumor RNA</measure>
    <time_frame>Day of surgery</time_frame>
    <description>Molecular classification of tumors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HLA (human leukocyte antigen) typing</measure>
    <time_frame>Day of surgery</time_frame>
    <description>Prediction of neoantigens implicated in the intratumoral immune response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunophenotyping of intratumoral lymphocytes</measure>
    <time_frame>Day of surgery</time_frame>
    <description>Immunologic characteristic of tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Densities of lymphocytes T CD8 (cluster of differentiation 8)</measure>
    <time_frame>Day of surgery</time_frame>
    <description>Immunologic characteristic of tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Densities of macrophages M2 (CD68, CD163)</measure>
    <time_frame>Day of surgery</time_frame>
    <description>Immunologic characteristic of tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Densities of fibroblasts (SMA)</measure>
    <time_frame>Day of surgery</time_frame>
    <description>Immunologic characteristic of tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of lymphoid structures in immune infiltrate : DC-Lamp (Dendritic cell-lysosomal associated membrane protein)/CD3</measure>
    <time_frame>Day of surgery</time_frame>
    <description>Immunologic characteristic of tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of lymphoid structures in immune infiltrate : CD20/CD3</measure>
    <time_frame>Day of surgery</time_frame>
    <description>Immunologic characteristic of tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression profile of immune and stromal metagenes</measure>
    <time_frame>Day of surgery</time_frame>
    <description>Immunologic characteristic of tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of lymphocytes T CD4 (activated/inhibited)</measure>
    <time_frame>Inclusion and 4 weeks after surgery</time_frame>
    <description>Immunologic characteristic of circulating cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of lymphocytes T CD8 (activated/inhibited)</measure>
    <time_frame>Inclusion and 4 weeks after surgery</time_frame>
    <description>Immunologic characteristic of circulating cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treg profile</measure>
    <time_frame>Inclusion and 4 weeks after surgery</time_frame>
    <description>Immunologic characteristic of circulating cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MHC (major histocompatibility complex) peptide binding : Elispot</measure>
    <time_frame>Inclusion and 4 weeks after surgery</time_frame>
    <description>Immunologic characteristic of circulating cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine assay : Luminex</measure>
    <time_frame>Inclusion and 4 weeks after surgery</time_frame>
    <description>Immunologic characteristic of circulating cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenesis markers assay</measure>
    <time_frame>Inclusion and 4 weeks after surgery</time_frame>
    <description>Immunologic characteristic of circulating cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complement components assay</measure>
    <time_frame>Inclusion and 4 weeks after surgery</time_frame>
    <description>Immunologic characteristic of circulating cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcriptomic profile of urinary RNAs</measure>
    <time_frame>Inclusion</time_frame>
    <description>Expression profile of immune gene in urine</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Colorectal Adenocarcinoma</condition>
  <condition>Hepatic Carcinoma</condition>
  <condition>Kidney Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Colorectal cancer</arm_group_label>
    <description>Patient with stage III colon carcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kidney cancer</arm_group_label>
    <description>Patient with clear cell kidney carcinoma more than 4 cm surgically removed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liver cancer</arm_group_label>
    <description>Patient with advanced hepatocellular carcinoma : biopsy or resected BCLC (Barcelona Clinic Liver Cancer) stage B or C for diagnostic and/or therapeutic purposes</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples, urine collection, tumor sample and tumor microenvironment sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with colorectal, kidney or liver cancers.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  for colorectal cancer group : patient with stage III colon carcinoma

          -  for kidney cancer group : patient with primary clear cell carcinoma more than 4 cm

          -  for liver cancer group : patient with advanced hepatocellular carcinoma : biopsy or
             resected BCLC (Barcelona Clinic Liver Cancer) stage B or C

          -  patients who have consented to the study

        Exclusion Criteria:

          -  Patients receiving neoadjuvant therapy are not eligible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pierre Laurent-Puig, MD, PhD</last_name>
    <phone>00331 42 86 20 81</phone>
    <email>pierre.laurent-puig@parisdescartes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eric Tartour, MD, PhD</last_name>
    <email>eric.tartour@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AP-HP Jean Verdier Hospital</name>
      <address>
        <city>Bondy</city>
        <zip>93140</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Charles Nault, MD</last_name>
      <email>jean-charles.nault@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jessica Zucman-Rossi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Peyromaure, MD, PhD</last_name>
      <email>michael.peyromaure@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>JÃ©rÃ´me Alexandre, MD, PhD</last_name>
      <email>jerome.alexandre@aphp.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>AP-HP European Georges Pompidou Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Laurent-Puig, MD, PhD</last_name>
      <email>pierre.laurent-puig@parisdescartes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Eric Tartour, MD, PhD</last_name>
      <email>eric.tartour@aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Pierre Laurent-Puig, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>StÃ©phane Oudard, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien TaÃ¯eb, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Tartour, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2017</study_first_submitted>
  <study_first_submitted_qc>May 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2017</study_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>European Georges Pompidou Hospital</investigator_affiliation>
    <investigator_full_name>Pierre Laurent-Puig</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>exhaustive genetic and immunological analyses</keyword>
  <keyword>targeted therapies</keyword>
  <keyword>colon cancer</keyword>
  <keyword>kidney cancer</keyword>
  <keyword>liver cancer</keyword>
  <keyword>immunological tumor microenvironment</keyword>
  <keyword>tumor microenvironment heterogeneity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The IPD (individual participant data) will not be shared. To protect confidentiality and integrity of patient information, only investigators of the study will have a regulated access to data with authorizations.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

